Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 2
2008 1
2010 1
2012 1
2013 3
2014 5
2015 2
2016 2
2017 3
2018 2
2019 3
2020 4
2021 4
2022 4
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

PubMed for id: 1680360

30 results

Results by year

Filters applied: . Clear all
Page 1
Nadofaragene Firadenovec: First Approval.
Lee A. Lee A. Drugs. 2023 Mar;83(4):353-357. doi: 10.1007/s40265-023-01846-z. Drugs. 2023. PMID: 36856952 Free PMC article. Review.
Epigenetic Regulation in Urothelial Carcinoma.
Li K, Qi L, Tang G, Xu H, Li Z, Fan B, Li Z, Li Y. Li K, et al. Curr Mol Med. 2024;24(1):85-97. doi: 10.2174/1566524023666221221094432. Curr Mol Med. 2024. PMID: 36545729 Review.
Multiparametric Classification of Non-Muscle Invasive Papillary Urothelial Neoplasms: Combining Morphological, Phenotypical, and Molecular Features for Improved Risk Stratification.
Montes-Mojarro IA, Hassas S, Staehle S, Sander P, Harland N, Serna-Higuita LM, Bonzheim I, Bösmüller H, Stenzl A, Fend F. Montes-Mojarro IA, et al. Int J Mol Sci. 2022 Jul 23;23(15):8133. doi: 10.3390/ijms23158133. Int J Mol Sci. 2022. PMID: 35897708 Free PMC article. Review.
Biomarker-Oriented Therapy in Bladder and Renal Cancer.
Scholtes MP, Alberts AR, Iflé IG, Verhagen PCMS, van der Veldt AAM, Zuiverloon TCM. Scholtes MP, et al. Int J Mol Sci. 2021 Mar 11;22(6):2832. doi: 10.3390/ijms22062832. Int J Mol Sci. 2021. PMID: 33799514 Free PMC article. Review.
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.
Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Svatek RS, Mashni J Jr, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown G, Canter D, Luchey A, Lotan Y, Krupski T, Inman BA, Williams MB, Cookson MS, Keegan KA, Andriole GL Jr, Sankin AI, Boyd A, O'Donnell MA, Sawutz D, Philipson R, Coll R, Narayan VM, Treasure FP, Yla-Herttuala S, Parker NR, Dinney CPN. Boorjian SA, et al. Lancet Oncol. 2021 Jan;22(1):107-117. doi: 10.1016/S1470-2045(20)30540-4. Epub 2020 Nov 27. Lancet Oncol. 2021. PMID: 33253641 Free PMC article. Clinical Trial.
30 results